Examining differences in molecular testing for lung cancer patients
Disparities in molecular testing among non-small cell lung cancer patients
This study looks at how different groups of people with non-small cell lung cancer, especially Black patients, may not be getting the genetic tests they need to find the best treatments, and it aims to understand what’s stopping them so that everyone can have fair access to life-saving therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11064424 on NIH RePORTER |
What this research studies
This research investigates the disparities in molecular testing among patients with non-small cell lung cancer (NSCLC), focusing on how genetic testing can influence treatment options. It aims to identify barriers that prevent certain groups, particularly Black patients, from receiving appropriate molecular testing, which is crucial for accessing targeted therapies and immunotherapies. By analyzing data on testing rates and treatment outcomes, the study seeks to improve equitable access to life-saving treatments for all lung cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include non-small cell lung cancer patients, particularly those from diverse racial backgrounds who may face disparities in molecular testing.
Not a fit: Patients with lung cancer who are not eligible for molecular testing or those with other types of lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved access to personalized cancer treatments for underserved populations, ultimately enhancing survival rates.
How similar studies have performed: Previous research has shown that addressing disparities in cancer treatment can lead to improved outcomes, suggesting that this approach has potential for success.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Taioli, Emanuela — Icahn School of Medicine at Mount Sinai
- Study coordinator: Taioli, Emanuela
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.